

**MOLECULAR ANALYSIS OF INDONESIAN LCA  
PATIENTS AND *IN VITRO* SPLICE CORRECTION  
FOR *CEP290*-ASSOCIATED LCA**

***ANALISIS MOLEKULER PADA PASIEN LCA INDONESIA DAN  
KOREKSI PROSES SPLICING SECARA IN VITRO PADA LCA  
TERKAIT CEP290***



**THESIS**

**Submitted to fulfill the assignment and fit-out requisite in passing  
Post Graduate Program**

**Master of Biomedical Science**

**Widya Eka Nugraha  
22010112420049**

**Supervisors:**

**Prof. Sultana MH Faradz, MD, Ph.D  
Kentar A Sulakso, MD, MSi.Med, Sp.M (K)**

**FACULTY OF MEDICINE  
DIPONEGORO UNIVERSITY SEMARANG  
2015**

**THESIS**

MOLECULAR ANALYSIS OF INDONESIAN LCA PATIENTS AND  
*IN VITRO* SPLICE CORRECTION FOR *CEP290*-ASSOCIATED LCA

Arranged by  
Widya Eka Nugraha, MD  
22010112420049

Has been defended in front of the defense committee on May, 19<sup>th</sup> 2015

And has been approved by:

**The Netherlands,**  
Principal Supervisor,

Dr. Rob WJ Collin

Supervisor,

Dr. Alex Garanto Iglesias

**Indonesia,**  
Principal Supervisor,

Prof. Sultana MH Faradz, MD, PhD  
NIP: 1952 0202 1979 012 001

Supervisor,

Kentar A Sulakso, MD, MSi.Med, Sp.M(K)  
NIP: 1968 1128 1998 03 1 001

Approved by,  
Head of Master Degree Program in Biomedical Science  
Faculty of Medicine Diponegoro University

Dr. Achmad Zulfa Juniarto, M.Si.Med, Sp.And, Ph.D  
NIP: 19700608 1997021 001

## **DECLARATION**

I hereby declare that this submission is my own work and that, to the best of my knowledge and belief, it contains no material previously published or written by another person nor material which to a substantial extent has been accepted for the award of any other degree or diploma of the university or other institute of higher learning, except where due acknowledgement is made in the text.

Semarang, March 2015

Widya Eka Nugraha

## ACKNOWLEDGEMENT

It is an honor for me to express my gratitude to everyone who have helped and supported me to finish this thesis. First of all, I would like to thank to Prof. Dr. Sultana MH Faradz, Ph.D for her advice, guidance, and support in my master program from the beginning till the end despite her own tight schedule. Thank you to dr. Kentar A Sulakso, Sp.M, MSi.Med for his support, clinical advice, and supervision in writing this thesis.

I would also like to express my gratitude to Prof. Rob WJ Collin, head of Blindness Genetic Therapy research group in the Department of Human Genetics of Radboud University Medical Centre, The Netherlands, for his kind supervision during my internship there. I am so thankful to Alex Garanto, Ph.D for his superb teaching and explanation to all that matters in my research.

It was a great experience to do research in the blindness genetic therapy lab with the help from Lonneke Duijkers as a technician, Galuh Astuti, Julio CC Serrano, Muriel Messchaert, as a Ph.D student, Manon Oud as a MSc student, and Arjen Henkes as bioinformatician.

I would also like to thank all the people from Center for Biomedical Research (CEBIOR), Semarang, Indonesia, Rita Indriati, Inthus Apriasa, Evi Nurwulan, Lusi Suwarsi, Wiwik Lestari, and Dwi Kustiani for their assistance during my master study.

I will always be grateful to be a part of Batch 7 of Masters in Biomedical Science Majoring in Genetic Counseling together with my beloved wife, Iffa Mutmainah, Mitayani, Catharina Endah W, Nura Eky V, Cinta C Rudianto, and Rendy R Pohan. Your warm companion supports me to complete my study.

My utmost gratitude and sincere thanks goes to my beloved parents, Eko Bambang Setyawan, S.E, and Dyah Adiati Warsitosiwi for all the genuine love and limitless support throughout the study. I will never be able to redeem everything you have done for me.

The opportunity to be a part of Master Student in CEBIOR and to have my research done In The Netherlands would not have been possible without the scholarship from Biro Perencanaan Kerja Sama Luar Negeri (BPKLN), Ministry of Education, Indonesia, especially DR. AB Susanto, MSc. as the coordinator of Beasiswa Unggulan. Finally, I would like to

thank all of the Master's degree and Fellowship coordinators, especially Prof. Dr. Sultana MH Faradz, Ph.D, dr. Tri Indah Winarni MSi.Med, Ph.D, and Ms. Ardina Apriliani S.E.

# CURRICULUM VITAE

Name : Widya Eka Nugraha  
Sex : Male  
Place & Date of birth : Bekasi, November 2<sup>nd</sup>, 1988  
Latest Degree : Medical Doctor  
Address : Poncol Jaya Block C3 No.2 RT/RW 003/019, Jaka Sampurna,  
Bekasi Barat P.O.BOX 17145  
Phone : +62856 8042 164  
E-mail : [widyaekan@gmail.com](mailto:widyaekan@gmail.com)

## Educational Background

2006-2010 : Diponegoro University, Medical Faculty (Bachelor degree)  
2010-2012 : Diponegoro University, Medical Faculty (Medical Doctor)  
2013-Present : Post Graduate Program Diponegoro University, Master in Biomedical Science  
Majoring in Genetic Counseling (Twinning Program with Radboud  
University Medical Centre Nijmegen, The Netherlands)

## Experience

2013-2014 : Department of Human Genetics, Radboud University Medical Centre,  
Nijmegen, The Netherlands: Internship Master Student

## Trainings and Courses

2013 : 11<sup>th</sup> Medical Genetic Course: From Basic to Clinic, Semarang  
2013 : Cardiogenetics and Its Clinical Management, Semarang  
2013 : Workshop on Writing International Research Grants and Publication,  
Semarang  
2013 : Molecular Biology: A Recent Update, Semarang  
2013 : Gene Therapy Seminar, Semarang  
2013 : 3<sup>rd</sup> International Seminar on Autism and Fragile-X Syndrome, Semarang

- 2014 : Novel Therapies for Inherited Retinal Dystrophies, Nijmegen The Netherlands
- 2014 : Clinical Master Class for Inherited Retinal Dystrophies, Nijmegen
- 2014 : Technical Master Class for Inherited Retinal Dystrophies, Nijmegen
- 2015 : Hands-on workshop on cytogenetic and molecular genetics. Semarang

### **Scientific Paper**

- 2010 : Correlation Between Intracranial Pressure Based On CT-Scan Imaging and Blood Glucosae Level in Head Injury Patient. Undergraduate thesis. Medical Faculty of Diponegoro University, Semarang.

### **Scholarship**

- 2013 : Excellent Scholarship Program of The Bureau of Planning and International Cooperation, Ministry of National Education, Government of Indonesia.

### **TOEFL score**

- 2010 : 550

## CONTENTS

<b>TITLE</b> .....	i
<b>APPROVAL SHEET</b> .....	ii
<b>DECLARATION</b> .....	iii
<b>ACKNOWLEDGEMENT</b> .....	iv
<b>CURRICULUM VITAE</b> .....	vi
<b>CONTENTS</b> .....	viii
<b>ABBREVIATIONS</b> .....	xii
<b>LIST OF TABLES</b> .....	xvi
<b>LIST OF FIGURES</b> .....	xvii
<b>GLOSSARY</b> .....	xviii
<b>ABSTRACT</b> .....	xix
<b>CHAPTER 1 INTRODUCTION</b> .....	1
1.1 Background.....	1
1.2 Research Question.....	2
1.3 Research Purposes.....	2
1.3.1 General Research Purposes.....	2
1.3.2 Specific Research Purpose.....	2
1.4 Research Benefits.....	2
1.5 Research Originality.....	2
<b>CHAPTER 2 LITERATURE REVIEW</b> .....	3
2.1 Leber Congenital Amaurosis.....	4
2.1.1 Clinical Characteristics.....	4
2.1.2 Genetic Causes and Heritability of Leber Congenital Amaurosis.....	6
2.1.3 <i>CEP290</i> .....	8
2.2 Therapeutic Strategies.....	10
2.2.1 Gene Augmentation Therapy.....	10



2.2.1.1	Lentiviral Vector.....	10
2.2.1.2	Adeno-associated Viral Vector.....	10
2.2.1.3	Nanoparticles.....	12
2.2.2	Antisense Oligonucleotide Based Therapy.....	12
2.2.2.1	AON sequences.....	13
2.2.2.2	Chemical Structure of AON.....	13
<b>CHAPTER 3</b>	<b>RESEARCH METHODS.....</b>	<b>14</b>
3.1	Research Field.....	14
3.2	Research Location.....	14
3.3	Research Period.....	14
3.4	Research Design.....	14
3.5	Population and sample.....	14
3.5.1	Population.....	14
3.5.2	Sample.....	14
3.5.2.1	Inclusion Criteria.....	15
3.5.2.2	Exclusion Criteria.....	15
3.6	Research Variable.....	15
3.6.1	Diagnostic Study.....	15
3.6.2	Functional Study.....	15
3.7	Diagnostic Study: Mutational Analysis of Indonesian LCA Patients.....	15
3.7.1	DNA Isolation.....	15
3.7.2	Primer Design.....	16
3.7.3	Polymerase Chain Reaction (PCR).....	16
3.7.3.1	ARMS-PCR.....	16
3.7.3.2	Regular PCR.....	16
3.7.4	Sanger Sequencing.....	17
3.7.5	Restriction Fragment Length Polymorphism (RFLP).....	17

3.8	Functional Studies: Optimization of Antisense Oligonucleotide (AON) Therapeutic Approach for LCA.....	17
3.8.1	Cell Culture.....	17
3.8.2	Transfection.....	17
3.8.3	RNA Isolation and Reverse Transcription PCR.....	18
3.8.4	Western Blot.....	18
3.8.5	Immunocytochemistry.....	18
3.8.6	Statistical Analysis.....	19
3.9	Research Flow.....	19
3.9.1	Diagnostic Study Workflow.....	20
3.9.2	Functional Study Workflow.....	21
3.10	Data Analysis.....	22
3.11	Research Ethics.....	22
	<b>CHAPTER 4 RESULTS</b> .....	23
4.1	Molecular Genetic Analysis of Indonesian LCA Patients.....	23
4.1.1	Clinical Findings.....	24
4.1.2	Molecular Findings.....	24
4.2	AON Optimization of <i>CEP290</i> -associated LCA Treatment.....	26
4.2.1	Transcriptional Analysis.....	26
4.2.2	Western Blot and Protein Quantification.....	28
4.2.3	Immunocytochemistry.....	29
	<b>CHAPTER 5 DISCUSSION</b> .....	31
5.1	Molecular Genetic Analysis of Indonesian LCA Patients.....	32
5.2	AON Optimization for <i>CEP290</i> -associated LCA Patients.....	32
5.3	Progress of Gene Therapy in Retinal Dystrophies.....	33
5.3.1	<i>RPE65</i> -associated LCA.....	34
5.3.2	Choroideremia.....	34

5.4	Therapeutic Possibilities for <i>CEP290</i> -associated LCA.....	34
	<b>CHAPTER 6 CONCLUSION AND FUTURE DIRECTIONS.....</b>	<b>36</b>
6.1	Conclusion.....	36
6.2	Future Directions.....	36
	<b>CHAPTER 7 SUMMARY .....</b>	<b>37</b>
	<b>REFERENCES .....</b>	<b>39</b>
	<b>APPENDICES .....</b>	<b>44</b>

## ABBREVIATIONS

2'-MOE	2'Methoxy-Ethoxy
2'-OMe	2'-O-Methyl
AAV/rAAV	Adeno-Associated Virus / Recombinant AAV
<i>ABCA4</i>	Adenosine Triphosphate-Binding Cassette, Sub-Family A, Member 4
<i>ACTB</i>	Actin Beta
ACHM	Achromatopsia
<i>AIPL1</i>	Aryl Hydrocarbon Receptor Interacting Protein-like 1
AON	Antisense Oligonucleotide
ARMS-PCR	Amplification Refractory Mutation System - PCR
<i>BBS4</i>	Bardet-Biedl Syndrome 4
BCA	Bicinchonic Acid
BSA	Bovine Serum Albumin
<i>CABP4</i>	Calcium Binding Protein 4
Cap	Capsid
CB	Chicken Beta actin
<i>CEP290</i>	Centrosomal Protein 290 kDa
CD	Cone Dystrophy
CEBIOR	Centre for Biomedical Research
cGMP	Cyclic Guanosine Monophosphate
CHM	Choroderemia
CK30PEG-NP	CK30 Polyethylene Glycol-Nano Particles
CORS	Cerebello-Oculo-Renal Syndrome
<i>CRB1</i>	Crumbs Family Member 1
CRD	Cone-Rod Dystrophy

<i>CRX</i>	Cone-Rod Homeobox
DAPI	4', 6-diaminidino-2-phenylindole
DMEM	Dulbecco's Modified Eagle Medium
DNA/cDNA	Deoxyribo Nucleic Acid / Complementary DNA
<i>DTHD1</i>	Death Domain Containing 1
EDTA	Ethylendiaminetetraacetic acid
EIAV	Equine Infectious Anemia Virus
ERG	Electroretinogram
ESE-Finder	Exonic Splicing Enhancer-Finder
<i>GDF6</i>	Growth Differentiation Factor 6
GT	Gene Therapy
<i>GUCY2D</i>	Guanylate Cyclase 2D
hRPE65	Human RPE65
<i>IBD</i>	Identity by Descent
<i>IMPDH1</i>	Inosine 5'-Monophosphate Dehydrogenase 1
iPSCs	Induced Pluripotent Stem Cells
IRD	Inherited Retinal Dystrophies
ITRs	Inverted Terminal Repeats
<i>IQCB1</i>	IQ Motif Containing B1
JSRD	Joubert Syndrome and Related Disorders
kDa	Kilodalton
<i>KCNJ13</i>	Potassium Inwardly-Rectifying Channel, Subfamily J, Member 13
LCA	Leber Congenital Amaurosis
<i>LCA5</i>	Leber Congenital Amaurosis 5
LINE	Long Interspersed Nuclear Elements
LP	Light Perception
<i>LRAT</i>	Lecithin Retinol Acyltransferase

LV	Lentivirus
MEM	Minimum Essential Media
<i>MERTK</i>	c-mer Proto-Oncogen Tyrosine Kinase
MIPs	Molecular Inversion Probes
MKS	Meckel-Gruber Syndrome
<i>MYO7A</i>	Myosin VIIA
NaCl	Natrium Chloride
<i>NMNAT1</i>	Nicotinamide Nucleotide Adenyltransferase 1
NP	Nano Particles
NUB1	NEDD8 Ultimate Buster 1
OMIM	Online Mendelian Inheritance in Man
<i>OTX2</i>	Orthodenticle Homeobox 2
PBS	Phosphate-Buffered Saline
POD	Peptide Ocular Delivery
PPRPE	Preserved Para-arteriolar Retinal Pigment Epithelium
PVDF	Polyvinylidene Difluorida
<i>RD3</i>	Retinal Degeneration 3
<i>RDH12</i>	Retinol Dehydrogenase 12
Rep	Replication
REP1	Rab Escort Protein 1
RFLP	Restriction Fragment Length Polymorphism
RIPA	Radio Immunoprecipitation Assay
RNA/mRNA	Ribo Nucleic Acid / Messenger RNA
RP	Retiniti Pigmentosa
RPE	Retinal Pigment Epithelium
<i>RPE65</i>	Retinal Pigment Epithelium-Specific Protein 65 kDa
<i>RPGRIP1</i>	Retinitis Pigmentosa GTPaseRegulator Interacting Protein 1

RT-PCR	Reverse Transcription - PCR
sFLT01	Soluble Fms-Like Tyrosine Kinase 1 Receptor
siRNA	Small Interference RNA
SLS	Senior-Loken Syndrome
SNC	Substantia Nigra pars Compacta
<i>SPATA7</i>	Spermatogenesis Associated 7
SRp55	Serine-Arginine rich Protein 55 kDa
SRp40	Serine-Arginine rich Protein 40 kDa
STGD	Stargardt's Disease
TPR	Tetratricopeptide Repeat
<i>TULP1</i>	Tubby-like Protein 1
VMD2	Vitelliform Macular Dystrophy 2
WT	Wild Type

## LIST OF TABLES

<b>Table 1.</b> Fundus photography results of LCA patients with known mutations in causative genes.....	5
<b>Table 2.</b> Mutation identification strategy. ....	6
<b>Table 3.</b> Prevalence of LCA causative genes. ....	7
<b>Table 4.</b> Vectors used in clinical trial for various retinal diseases. ....	11
<b>Table 5.</b> AAV serotype and target tissue. ....	12
<b>Table 6.</b> Molecular findings of Indonesian LCA patients. ....	24
<b>Table 7.</b> Efficacy of AONs in serial dilutions. ....	27



## LIST OF FIGURES

<b>Figure 1.</b> Anatomy of the eye and retinal structure. ....	3
<b>Figure 2.</b> Classification of IRDs according to age progression and cell involvement. ....	4
<b>Figure 3.</b> Mutation spectrum in <i>CEP290</i> . ....	9
<b>Figure 4.</b> Chemical structure of AON. ....	13
<b>Figure 5.</b> Schematic representation of diagnostic study workflow. ....	20
<b>Figure 6.</b> Workflow for functional studies to optimize the potential of AON-based approach. ....	21
<b>Figure 7.</b> Pedigrees of the families analyzed in this study. ....	23
<b>Figure 8.</b> Splicing prediction for c.33G>C variant in <i>AIPL1</i> . ....	25
<b>Figure 9.</b> Splicing prediction for c.970C>A variant in <i>AIPL1</i> . ....	25
<b>Figure 10.</b> Schematic representation of AONs. ....	26
<b>Figure 11.</b> Transcriptional Analysis. ....	28
<b>Figure 12.</b> Immunodetection and protein quantification of GT2, GT4, and GT22. ....	29
<b>Figure 13.</b> Immunocytochemistry and statistical analysis of GT2, GT4, GT22. ....	30
<b>Figure 14.</b> <i>AIPL1</i> protein domain structures. ....	31

## GLOSSARY

PCR	Polymerase Chain Reaction. Molecular technique to amplify a single or multiple copies of a piece of DNA over several orders of magnitude.
RFLP	Restriction Fragment Length Polymorphism. A variation in the length of restriction fragments formed from a certain restriction enzyme in a sample of DNA
AON	Antisense Oligonucleotide. A synthetic polymers which are created from 15-20 chemically-modified deoxynucleotides or ribonucleotides in an antisense sequence (3' → 5'), complementary to the sense sequence of an mRNA.
Centrosome	An organelle close to the nucleus of a cell that consist of the centrioles and from which the spindle fibers develop in cell division.
LCA	Leber Congenital Amaurosis. A genetic disorder that mainly affects the retina and cause severe visual impairment to blindness.

## ABSTRACT

**Background:** Leber congenital amaurosis (LCA) is an autosomal recessive retinal disorder, characterized by an early-onset visual loss, amaurotic pupils, and retinal degeneration. Only a few studies have been described about Indonesian LCA patients. Pre-clinical studies have shown that antisense oligonucleotide (AON) restored the aberrant splicing caused by a recurrent intronic mutation in the *CEP290* gene. This study combined diagnostic study in Indonesian LCA patients and in-vitro AON-based therapy for LCA.

**Methods:** *CEP290*, *CRB1*, *GUCY2D*, and *AIP1* genes were screened in 4 LCA patients from 3 unrelated families by amplification refractory mutation system (ARMS) PCR or Sanger sequencing. Meanwhile, 29 different AONs (GT1 to GT29) with two chemistries were designed and tested by RT-PCR, Western blot, and immunocytochemistry.

**Results:** Three variants were found in *AIP1* gene: p.E318G, p.R324R, and p.G11G. Interestingly, p.E318G was predicted as a disease causing mutation by MutationTaster program while p.R324R and p.G11G were predicted to cause a splicing alteration by ESE-finder splicing prediction. On the other hand, from 29 AON tested in this study, 4 AONs worked efficiently in correcting the aberrant splicing, increasing the CEP290 protein, and restoring the cilium length, at low concentrations.

**Conclusions:** The molecular genetic analysis of Indonesian LCA patients in this study revealed three new candidate variants as a LCA causative mutation in *AIP1*: p.E318G, p.R324R, and p.G11G. From 29 AONs tested in this study, GT2, GT3, and GT4 were the most efficient. Remarkably, these AONs shared the same chemical modification.

**Keywords:** Leber congenital amaurosis, splicing mutation, antisense oligonucleotide, *CEP290*

# **ANALISIS MOLEKULER PADA PASIEN LCA INDONESIA DAN KOREKSI PROSES *SPLICING* SECARA *IN VITRO* UNTUK LCA TERKAIT *CEP290***

**WIDYA EKA NUGRAHA**

## **ABSTRAK**

**Latar Belakang:** Leber Congenital Amaurosis (LCA) adalah suatu penyakit genetic yang diturunkan secara autosomal resesif dan ditandai dengan hilang penglihatan sejak dini, pupil yang amaurotik, dan degenerasi retina. Penelitian tentang pasien LCA di Indonesia masih terbatas. Sementara, studi pre-klinis menunjukkan bahwa penggunaan *antisense oligonucleotide* (AON) dapat mengembalikan transkrip abnormal pada mutasi gen *CEP290* yang menjadi penyebab tersering penyakit LCA. Penelitian ini menggabungkan studi diagnostik pada pasien LCA Indonesia sekaligus koreksi proses *splicing* secara *in vitro* menggunakan AON.

**Metode:** Strategi identifikasi mutasi melibatkan gen *CEP290*, *CRB1*, *GUCY2D*, dan *AIPL1* pada 4 pasien dari 3 keluarga yang berbeda. Teknik molekuler yang digunakan yaitu *amplification refractory mutation system* (ARMS) PCR atau Sanger sequencing. Sementara itu, 29 molekul AON yang berbeda (GT1-GT29) diuji-coba menggunakan teknik *reverse transcriptase* (RT) PCR, *Western blot*, dan *immunocytochemistry*.

**Hasil:** Ditemukan tiga varian pada gen *AIPL1*: p.E318G, p.R324R, dan p.G11G. Varian p.E318G diprediksi sebagai mutasi penyebab penyakit dengan program *MutationTaster* sementara varian p.R324R dan p.G11G diprediksi menyebabkan gangguan proses *splicing* oleh program *ESE-finder splicing prediction*. Studi fungsional menunjukkan bahwa dari 29 AON yang diuji-cobakan. GT2, GT3, dan GT4 merupakan AON yang paling efisien dalam mengoreksi proses *splicing*, meningkatkan protein CEP290, dan mengembalikan panjang *cilium* pada konsentrasi minimum.

**Kesimpulan:** Analisis molekuler pada studi ini mengungkapkan tiga kandidat varian baru sebagai mutasi penyebab LCA untuk gen *AIPL1*: p.E318G, p.R324R, dan p.G11G. Dari 29 AON yang diuji, GT2, GT3, GT4 adalah yang paling efisien. Ketiga AON memiliki kerangka molekuler yang sama.

**Kata kunci:** Leber congenital amaurosis, mutasi *splicing*, *antisense oligonucleotide*, *CEP290*.